Medrx Co.,Ltd.
4586・Growth Market・Pharmaceuticals
Governance
In March 2024, the company transitioned from a company with a Board of Corporate Auditors to a company with an Audit and Supervisory Committee. The Board of Directors consists of 9 members (5 full-time and 4 outside directors), and all 4 outside directors also serve as Audit and Supervisory Committee members. No nomination committee or compensation committee has been confirmed to be established.
Risk Management
The Company has established Risk Management Regulations and built a system centered on the Board of Directors to enable early detection and prevention of risks. The internal audit officer, the Audit and Supervisory Committee, and the accounting auditor collaborate from independent standpoints, while the Corporate Management Department is responsible for the continuous improvement of internal controls. A framework is also in place to obtain advice as needed from external advisors such as lawyers and tax accountants.
Shareholder Returns
Continuation of no dividend payment. Annual dividend per share is ¥0 for both FY2025 (ending December 2025) and FY2026 (ending December 2026). As the company is in the stage of upfront investment in research and development, it prioritizes retaining internal reserves and plans to consider profit distribution through dividends after the launch of new drugs and the recording of net income.
Dividend Policy
The annual dividend per share for FY2025 (ending December 2025) is ¥0 (¥0 at the end of the second quarter, ¥0 at year-end). The forecast for FY2026 (ending December 2026) is also an annual dividend of ¥0 (¥0 at the end of the second quarter, ¥0 at year-end). The company has continuously recorded operating losses and net losses since its founding, and as it has no distributable resources, it remains without dividends. The policy is to prioritize securing R&D funds and to focus on retaining internal reserves. In the future, at the time when new drugs under development are launched and net income attributable to owners of the parent is recorded, the company will consider implementing profit distribution through dividends while taking into account its business performance and financial position.
ESG
Sustainability initiatives are overseen collectively by the Board of Directors. The company positions human resource diversity as a top priority, adopting a policy of securing diverse talent regardless of gender, nationality, or race, and has introduced a discretionary labor system in its research division. Quantitative indicators and targets have not yet been set, and the company plans to consider them going forward through data collection and analysis. Consolidated employee headcount was 21 (as of the end of December 2025), with an average age of 49.7 years and average length of service of 12.4 years.
Last updated: March 19, 2026